CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon
Titel:
CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon
Auteur:
Venook, A. Niedzwiecki, D. Lenz, H.J. Innocenti, F. Mahoney, M.R. O'Neil, B. Shaw, J. Polite, B. Hochster, H. Atkins, J. Goldberg, R. Mayer, R. Schilsky, R. Bertagnolli, M. Blanke, C.